ADX-324

DRUG4 trials

Sponsors

Adarx Pharmaceuticals Inc., ADARx Pharmaceuticals, Inc.

Conditions

HAEHereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2

Phase 1

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Active, not recruitingNCT05691361

ADARx Pharmaceuticals, Inc.Hereditary Angioedema

Start: 2022-12-14End: 2027-12-31Target: 53Updated: 2026-06-16

Phase 3

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

RecruitingNCT06960213

ADARx Pharmaceuticals, Inc.HAE, Hereditary Angioedema, Hereditary Angioedema - Type 1 +1

Start: 2025-08-28End: 2027-12-31Target: 90Updated: 2026-09-10

STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Not yet recruitingCTIS2025-521352-38-00

Adarx Pharmaceuticals Inc.Hereditary Angioedema

Target: 36Updated: 2025-12-30

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Not yet recruitingCTIS2025-521353-16-00

Adarx Pharmaceuticals Inc.Hereditary Angioedema

Target: 23Updated: 2026-06-24